Archive #46085

Metadata

Bill Number: SB26-006
HTTP Status: 200
Valid JSON: Valid
Archived At: 2026-03-19 10:45:06 MDT
Created At: 2026-03-19 10:45:06 MDT

Parsed JSON

{
  "votes": [],
  "active": "T",
  "origin": "Senate",
  "lls_num": "26-0027",
  "session": "2026A",
  "subject": [
    "Health Care & Health Insurance"
  ],
  "bill_num": "SB26-006",
  "sponsors": [
    {
      "id": "KB002",
      "title": "Representative",
      "s_type": "Prime Sponsor",
      "chamber": "House",
      "full_name": "Kyle Brown",
      "last_name": "Brown",
      "first_name": "Kyle",
      "sponsor_order": "3"
    },
    {
      "id": "JA002",
      "title": "Senator",
      "s_type": "Prime Sponsor",
      "chamber": "Senate",
      "full_name": "Judy Amabile",
      "last_name": "Amabile",
      "first_name": "Judy",
      "sponsor_order": "1"
    },
    {
      "id": "DJ002",
      "title": "Senator",
      "s_type": "Prime Sponsor",
      "chamber": "Senate",
      "full_name": "Dafna Michaelson Jenet",
      "last_name": "Michaelson Jenet",
      "first_name": "Dafna",
      "sponsor_order": "2"
    }
  ],
  "bill_files": [
    {
      "url": "https://www.leg.state.co.us/CLICS/CLICS2026A/csl.nsf/0/3D7E2C986386BBF087258D04005ECBA5/$File/006_01.pdf",
      "date": "01/14/2026",
      "label": "Introduced",
      "url_html": "https://www.leg.state.co.us/CLICS/CLICS2026A/csl.nsf/0/3D7E2C986386BBF087258D04005ECBA5/$File/006_01.html",
      "lastModified": "01/13/2026 02:11:05 PM"
    }
  ],
  "committees": [
    {
      "id": "S_HHS_2026A",
      "name": "Health & Human Services",
      "chamber": "Senate"
    }
  ],
  "long_title": "Concerning parity for the use of non-opioid pain management drugs.",
  "bill_status": "In Committee - SEN Health & Human Services",
  "short_title": "Parity for Non-Opioid Pain Management Drugs",
  "bill_summary": "<html><body><p><t></t></p><p>The bill requires a health insurance carrier that provides prescription drug benefits to require that:</p><p><ul><li>The utilization review requirements, including prior authorization and step therapy, for a non-opioid drug prescribed and approved by the federal food and drug administration (FDA) for the treatment or management of chronic or acute pain (non-opioid pain management drug) are no more restrictive than the least restrictive utilization review requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain;<li>There is at least one clinically appropriate non-opioid prescription drug available as an alternative for each opioid prescription drug; and<li>The cost-sharing, copayment, or deductible for a non-opioid pain management drug is not greater than the cost-sharing, copayment, or deductible for an opioid drug prescribed for the treatment or management of chronic or acute pain.</li></ul><t></t></p><p>The bill requires the department of health care policy and financing to ensure that the utilization review requirements, including prior authorization or step therapy, for a non-opioid prescription drug prescribed and approved by the FDA for the treatment or management of chronic or acute pain are no more restrictive than the least restrictive utilization requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain.</p><p><br/><i>(Note: This summary applies to this bill as introduced.)</i></p></body></html>",
  "progress_bar": [
    {
      "end": "F",
      "label": "Introduced",
      "position": 1
    },
    {
      "end": "F",
      "label": "Under Consideration",
      "position": 2
    }
  ],
  "special_type": "",
  "bill_category": "Health Care Policy and Financing",
  "allow_testimony": "F",
  "amendment_files": [],
  "full_bill_topic": "Parity for Non-Opioid Pain Management Drugs",
  "long_bill_files": [],
  "GHG_report_files": [],
  "preamended_files": [],
  "bill_sub_category": "Medicaid (Medical Assistance)",
  "fiscal_note_files": [
    {
      "url": "https://www.leg.state.co.us/CLICS/CLICS2026A/csl.nsf/0/3D7E2C986386BBF087258D04005ECBA5/$File/SB006_00.pdf",
      "date": "03/10/2026",
      "label": "FN1",
      "url_html": "",
      "lastModified": "03/10/2026 08:45:12 AM",
      "label_detailed": "Initial Fiscal Note"
    }
  ],
  "is_budget_package": "No",
  "session_laws_files": "",
  "summarized_history": [
    {
      "date": "01/14/2026",
      "action": "Introduced In Senate - Assigned to Health & Human Services",
      "location": "Senate"
    }
  ],
  "research_note_files": [],
  "bill_sub_sub_category": "Other",
  "committee_report_files": [],
  "demographic_note_files": [],
  "updated_bill_summary_files": [],
  "budget_staff_analysis_files": [],
  "first_chamber_third_reading_date": "",
  "second_chamber_third_reading_date": ""
}

Raw Response

{"bill_num":"SB26-006","lls_num":"26-0027","origin":"Senate","short_title":"Parity for Non-Opioid Pain Management Drugs","full_bill_topic":"Parity for Non-Opioid Pain Management Drugs","long_title":"Concerning parity for the use of non-opioid pain management drugs.","special_type":"","bill_category":"Health Care Policy and Financing","bill_sub_category":"Medicaid (Medical Assistance)","bill_sub_sub_category":"Other","is_budget_package":"No","subject":["Health Care & Health Insurance"],"bill_status":"In Committee - SEN Health & Human Services","sponsors":[{"id":"KB002","title":"Representative","first_name":"Kyle","last_name":"Brown","full_name":"Kyle Brown","s_type":"Prime Sponsor","chamber":"House","sponsor_order":"3"},{"id":"JA002","title":"Senator","first_name":"Judy","last_name":"Amabile","full_name":"Judy Amabile","s_type":"Prime Sponsor","chamber":"Senate","sponsor_order":"1"},{"id":"DJ002","title":"Senator","first_name":"Dafna","last_name":"Michaelson Jenet","full_name":"Dafna Michaelson Jenet","s_type":"Prime Sponsor","chamber":"Senate","sponsor_order":"2"}],"committees":[{"id":"S_HHS_2026A","chamber":"Senate","name":"Health & Human Services"}],"first_chamber_third_reading_date":"","second_chamber_third_reading_date":"","summarized_history":[{"date":"01/14/2026","location":"Senate","action":"Introduced In Senate - Assigned to Health & Human Services"}],"progress_bar":[{"position":1,"label":"Introduced","end":"F"},{"position":2,"label":"Under Consideration","end":"F"}],"active":"T","session":"2026A","allow_testimony":"F","long_bill_files":[],"bill_files":[{"date":"01/14/2026","lastModified":"01/13/2026 02:11:05 PM","label":"Introduced","url":"https://www.leg.state.co.us/CLICS/CLICS2026A/csl.nsf/0/3D7E2C986386BBF087258D04005ECBA5/$File/006_01.pdf","url_html":"https://www.leg.state.co.us/CLICS/CLICS2026A/csl.nsf/0/3D7E2C986386BBF087258D04005ECBA5/$File/006_01.html"}],"fiscal_note_files":[{"date":"03/10/2026","lastModified":"03/10/2026 08:45:12 AM","label":"FN1","label_detailed":"Initial Fiscal Note","url":"https://www.leg.state.co.us/CLICS/CLICS2026A/csl.nsf/0/3D7E2C986386BBF087258D04005ECBA5/$File/SB006_00.pdf","url_html":""}],"research_note_files":[],"budget_staff_analysis_files":[], "preamended_files":[],"committee_report_files":[],"updated_bill_summary_files":[],"demographic_note_files":[],"GHG_report_files":[],"bill_summary":"<html><body><p><t></t></p><p>The bill requires a health insurance carrier that provides prescription drug benefits to require that:</p><p><ul><li>The utilization review requirements, including prior authorization and step therapy, for a non-opioid drug prescribed and approved by the federal food and drug administration (FDA) for the treatment or management of chronic or acute pain (non-opioid pain management drug) are no more restrictive than the least restrictive utilization review requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain;<li>There is at least one clinically appropriate non-opioid prescription drug available as an alternative for each opioid prescription drug; and<li>The cost-sharing, copayment, or deductible for a non-opioid pain management drug is not greater than the cost-sharing, copayment, or deductible for an opioid drug prescribed for the treatment or management of chronic or acute pain.</li></ul><t></t></p><p>The bill requires the department of health care policy and financing to ensure that the utilization review requirements, including prior authorization or step therapy, for a non-opioid prescription drug prescribed and approved by the FDA for the treatment or management of chronic or acute pain are no more restrictive than the least restrictive utilization requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain.</p><p><br/><i>(Note: This summary applies to this bill as introduced.)</i></p></body></html>","amendment_files":[],"session_laws_files":"","votes":[]}